Anti-IL-5 therapies for chronic obstructive pulmonary disease

Donovan, Tim; Milan, Stephen J; Wang, Ran; Banchoff, Emma; Bradley, Patrick; Crossingham, Iain

doi:10.1002/14651858.cd013432.pub2

Cited by 23 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the meta-analysis on anti-IL-5 in COPD patients already existed ( Donovan et al, 2020 ; Lan et al, 2020 ), study participants were not limited to eosinophilic COPD patients. To provide more accurate and stronger evidence for the efficacy of anti-IL-5 therapy in eosinophilic COPD patients, the current study differs in two ways from the previous meta-analysis ( Dave and Arjun, 2021 ): we only included eosinophilic COPD patients (peripheral blood eosinophil count of 3% or more or >150 cells per cubic millimeter) ( Balkissoon, 2018 ); we compared anti-IL-5 therapy in eosinophilic COPD and in asthma, which enabled a more robust assessment of the effect of anti-IL-5 therapy in eosinophilic COPD patients.…”

Section: Introductionmentioning

confidence: 99%

Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Background: Although the predominant airway inflammation in chronic obstructive pulmonary disease (COPD) is neutrophilic, approximately 20–40% of COPD patients present with eosinophilic airway inflammation. Compared with non-eosinophilic COPD patients, eosinophilic COPD patients are characterized by a greater number of total exacerbations and higher hospitalization rates. Furthermore, anti-interleukin-5 (IL-5) therapy, consisting of monoclonal antibodies (mAbs) targeting IL-5 or IL-5 receptor α (IL-5Rα), has been proven to be effective in severe eosinophilic asthma. This meta-analysis aimed to determine the efficacy and safety of anti-IL-5 therapy in eosinophilic COPD.Methods: We searched the PubMed, Web of Science, Embase, and Cochrane Library databases from inception to August 2020 (updated in June 2021) to identify studies comparing anti-IL-5 therapy (including mepolizumab, benralizumab, and reslizumab) with placebo in eosinophilic COPD patients.Results: Anti-IL-5 therapy was associated with a decrease in acute exacerbation rate (RR 0.89; 95% CI 0.84 to 0.95, I2 = 0%) and the severe adverse events (RR 0.90; 95% CI 0.84 to 0.97, I2 = 0%). However, no significant improvement was observed in pre-bronchodilator forced expiratory volume in 1 s (FEV1) (WMD 0.01; 95% CI −0.01 to 0.03, I2 = 25.9%), SGRQ score (WMD −1.17; 95% CI −2.05 to −0.29, I2 = 0%), and hospital admission rate (RR 0.91; 95% CI 0.78 to 1.07, I2 = 20.8%).Conclusion: Anti-IL-5 therapy significantly reduced the annual acute exacerbation rate and severe adverse events in eosinophilic COPD patients. However, it did not improve lung function, quality of life, and hospitalization rate.

show abstract

Section: Introductionmentioning

confidence: 99%

Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 84 Cochrane's analysis of anti-IL-5 therapies for COPD has concluded that there was probably little or no difference between the intervention and placebo for quality-of-life measures. 57 Apparently, there is also no major impact of these mAbs on lung function. 85 For other classes of mAbs, information is even more scarce.…”

Section: Discussionmentioning

confidence: 99%

“…A recent Cochrane systematic review that included six studies involving a total of 5542 participants concluded that mepolizumab and benralizumab probably reduce the rate of moderate and severe AECOPDs in the highly selected group of people who have both COPD and higher levels of blood eosinophils (patients with blood eosinophils at the higher end of the normal range as well as those with true blood eosinophilia). 57 …”

Section: Targeting T2-mediated Inflammation Using Mabsmentioning

confidence: 99%

An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease

Cazzola¹,

Ora²,

Cavalli³

et al. 2021

BTT

View full text Add to dashboard Cite

“…More recently, a Cochrane database analysis of 6 studies with 5542 participants who had COPD and were randomized to anti-IL-5 therapy demonstrated that mepolizumab probably reduced the rate of moderate–severe exacerbations in patients with > 150 eosinophils [ 53 ]. In addition, benralizumab reduced the rate of hospitalization in those with an eosinophil count > 220 cells/μl [ 53 ].…”

Section: Introductionmentioning

confidence: 99%

Eosinophilic Chronic Obstructive Pulmonary Disease

Weissler

Adams

2021

Lung

View full text Add to dashboard Cite

Recent therapeutic advances in the management of asthma have underscored the importance of eosinophilia and the role of pro-eosinophilic mediators such as IL-5 in asthma. Given that a subset of patients with COPD may display peripheral eosinophilia similar to what is observed in asthma, a number of recent studies have implied that eosinophilic COPD is a distinct entity. This review will seek to contrast the mechanisms of eosinophilia in asthma and COPD, the implications of eosinophilia for disease outcome, and review current data regarding the utility of peripheral blood eosinophilia in the management of COPD patients.

show abstract

Anti-IL-5 therapies for chronic obstructive pulmonary disease

Abstract: Anti-IL5 therapies for chronic obstructive pulmonary disease.

Cited by 23 publications

References 32 publications

Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease

Eosinophilic Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About